**Cost Effectiveness of NovaSure in the South African Private Health Sector**

By

Kutu Augustine Adebayo (PhD Economics) & Gavin George (PhD Economics)

Health Economics and HIV and Aids Research Division,

University of KwaZulu-Ntal,

South Africa.

***Corresponding author: kutuA@ukzn.ac.za***

**Abstract**

Abnormal Uterine Bleeding (AUB) has caused open concern among the health practitioners as it contributes substantially to medical care costs, putting a heavy economic burden on society, and as well as having effects on the quality of life and productivity of women who suffer from it. However, government has rolled out a NovaSure (a non- surgical treatment), compared to a hysterectomy (a surgical operation to remove all or part of the uterus) as a treatment option for dysfunctional and abnormal (heavy) bleeding. Therefore, there is an urgent need to determine the cost effectiveness of NovaSure as an alternative AUB treatment option in South Africa.